The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. - Wikidata - wikimedia - TriplyDB

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

http://www.wikidata.org/entity/Q54101394

about

Nosocomial spread of a Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit.Vancomycin heteroresistance in bloodstream isolates of Staphylococcus capitis Cloxacillin versus vancomycin for presumed late-onset sepsis in the Neonatal Intensive Care Unit and the impact upon outcome of coagulase negative staphylococcal bacteremia: a retrospective cohort study.Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.Identification of antigenic components of Staphylococcus epidermidis expressed during human infection.Characterization of coagulase-negative staphylococcal isolates from blood with reduced susceptibility to glycopeptides and therapeutic options.Vancomycin resistance in staphylococci.SdrG, a fibrinogen-binding bacterial adhesin of the microbial surface components recognizing adhesive matrix molecules subfamily from Staphylococcus epidermidis, targets the thrombin cleavage site in the Bbeta chain.Molecular epidemiology of Staphylococcus epidermidis in a neonatal intensive care unit over a three-year period.Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing.First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.In vitro activities of arylomycin natural-product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci Daptomycin dose-effect relationship against resistant gram-positive organisms Molecular characterization of methicillin-resistant Staphylococcus epidermidis clones: evidence of geographic dissemination.Antimicrobial-resistant, Gram-positive bacteria among patients undergoing chronic hemodialysis.Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment.Prophylactic use of vancomycin in adult cardiology and cardiac surgery.Heteroresistant Vancomycin Intermediate Coagulase Negative Staphylococcus in the NICU: A Systematic Review.Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri Foreign body infections due to Staphylococcus epidermidis.Molecular Epidemiology of a Vancomycin-Intermediate Heteroresistant Staphylococcus epidermidis Outbreak in a Neonatal Intensive Care Unit.Antibiotic resistance patterns of bacterial isolates from blood in San Francisco County, California, 1996-1999 Artificial opsonin enhances bacterial phagocytosis, oxidative burst and chemokine production by human neutrophils.Linezolid Treatment for Osteomyelitis due to Staphylococcus Epidermidis with Reduced Vancomycin Susceptibility.Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods.Vancomycin heteroresistance in coagulase negative Staphylococcus blood stream infections from patients of intensive care units in Mansoura University Hospitals, Egypt.Detection of methicillin-resistance gene in Staphylococcus epidermidis strains isolated from patients in Al-Zahra Hospital using polymerase chain reaction and minimum inhibitory concentration methods Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs.Emergence of vancomycin-intermediate Staphylococcus aureus and S. sciuri, Greece Vancomycin and daptomycin pharmacodynamics differ against a site-directed Staphylococcus epidermidis mutant displaying the small-colony-variant phenotype.INH-A21: a donor-selected Staphylococcal human immune globulin for the prevention of late-onset neonatal Staphylococcal infection.Antimicrobial proficiency testing of National Nosocomial Infections Surveillance System hospital laboratories.Vancomycin-intermediate Staphylococcus epidermidis: curio or omen?

P2860

Q24532922-C6965988-9F34-4E1B-93B8-E72943438FF1 Q24646621-4152649A-0579-4A4E-982D-679B25ADCFC9 Q25256319-E087F17F-C474-4D81-9DD3-DD5D0EF9286C Q30433993-777635DC-ED42-4678-8263-8AFDF01BF05A Q33251441-29E9B8B7-2E92-4019-9278-3773A43777BE Q33460707-931985D9-D2FE-4DB8-9742-91DE25B034C2 Q33906522-373A6BB8-344C-45FB-9422-4473779B9A50 Q33948050-9022E3E7-7B4C-428C-B017-5BEEBE65B755 Q33966785-644A8376-FEA6-4B80-936B-A63BEC43E286 Q33970955-0DE54F1C-511B-4172-A4D5-5D153FB6E5DA Q33971217-67D1DB9F-859A-4E0F-B24E-FC72EFD782F6 Q34737427-4934DF32-41AE-43A2-9D43-A47D397D349E Q34936759-65B91E5C-3242-4D37-A129-9937D5EC533E Q34944920-04AEACBC-33A5-45F7-983C-2D426AE4C496 Q34985828-F2C2B836-38E9-410F-AECF-9A3FB1FDB224 Q35009236-306A4822-4FE8-4DBF-92DF-6B04531D2673 Q35750208-0F544312-C856-44E3-BF99-AD3B941E65BD Q36157736-194A3B90-FBAD-4996-B219-03B07ED93109 Q36328966-877AC556-4A2F-4B2C-B128-972BCA7640CA Q36891450-AA2245CD-0492-46BF-8211-AB7CFD4B8726 Q37249440-39B6A717-8BC7-4BAD-9D7E-298788D4C21F Q37287797-AFBD0CFB-2BAF-4F36-A63C-019537A51A72 Q37320018-58F01B66-C54D-42E7-819E-90EF1DA55CAA Q40072409-7D36B9ED-949A-4FD8-B3A9-555F924BA7F4 Q40401780-E1D349E2-A171-43E1-9E54-69768C6F535C Q41428954-66546961-8F08-4B8A-A322-94F302C1137E Q41711192-5C81800B-2EF1-4F17-81CC-A73790852F6A Q41839959-3937A124-4409-496D-B42C-5C8DD8A31303 Q41874503-622B6595-9CA5-4144-A685-E1A0A2D1E7F0 Q42037140-2B5DD29A-FEED-47FE-881D-D3DB3403710F Q42535962-D0744FCC-07C4-4D8F-89CB-A40B219A9485 Q42545845-C537EA27-E28E-42EC-84B3-F1D98EF9EA22 Q44090632-C3CFF61A-2DF2-4C27-9943-49871CC5C2FE Q44464884-ED84D04C-2237-462A-9922-47925F7C2649 Q54101396-F038ABF0-0110-4580-AFD5-824CC1F83D74

P2860

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

http://www.wikidata.org/entity/Q54101394

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

@en

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

@nl

type

label

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

@en

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

@nl

prefLabel

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

@en

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

@nl

P1433

Q54101394-04AFA127-8F0B-4967-A50E-D96CA290A052

P1476

Q54101394-1F7AC392-545C-4102-8DDE-A04661727E16

P2093

Q54101394-0F5EFB71-7D6A-48DD-8B46-C5941B501A66

Q54101394-2756475D-624E-4141-BAD3-7A80DD337A15

Q54101394-3D6A152D-892E-4E81-9A97-0C593CCCBD78

Q54101394-55866A33-72CA-432C-806E-AE830A54CA95

Q54101394-61F6AF7F-3552-4E3E-B630-B40CD8FC5E97

Q54101394-8229ED50-9207-401D-94C9-971B81EA49A1

Q54101394-B8CD8C04-5AC7-4C73-AB9D-0A848AEC2123

Q54101394-BA9DB5B6-0ABE-4824-9862-16D618FFBCB3

Q54101394-BC6C7AC5-ECBD-47F2-BFFC-35605F0EA718

Q54101394-CA50F9C9-1C32-4793-91E9-C76A1576CF17

P2860

Q54101394-3E3CAF18-5D4A-4BAB-A4AB-43F28B659184

Q54101394-676FDA60-AC27-4FF5-9F90-3EBFD9233AA7

Q54101394-6CFFF005-20BE-4F7E-98CE-6949FBDD1F0C

Q54101394-76EE52E7-0671-42AB-B239-6E26BF5F78F9

Q54101394-8E93470C-3973-41B8-99DE-0ED43539C6FC

Q54101394-933E5C98-081B-4B70-952A-2565B3B5EB8E

Q54101394-BA696321-6B98-45AB-82EB-ADD0A71685EF

Q54101394-BA6C356A-4834-42E4-8729-7E80CBB2565B

Q54101394-DB520143-9767-48DD-9B5D-2669EF699507

Q54101394-DD3F6E87-5901-4C43-95C8-B86DA0FCFBB0

P304

Q54101394-42F39F35-CEFE-4B08-9F1C-6C6C21A247AE

P31

Q54101394-38DA2A0D-4AFA-4DD4-9417-E55A0D36C928

P356

Q54101394-9493D046-DFA8-4EBD-8BC4-103A04E19038

P433

Q54101394-458993D8-1548-4454-9A2A-9FE3369289CA

P478

Q54101394-153402CB-B8F7-4863-A586-AF0A77E24D0D

P577

Q54101394-E2293C2C-BB33-4F8F-909C-4F39C671EAB7

P698

Q54101394-C921FF34-9AF4-4B92-9EA1-3FD0DBB62B45

P356

P1433

Infection Control and Hospital Epidemiology

P1476

The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis.

@en

P2093

B Hill

http://www.w3.org/2001/XMLSchema#string

B Zimmer

http://www.w3.org/2001/XMLSchema#string

D O Garrett

http://www.w3.org/2001/XMLSchema#string

E Jochimsen

http://www.w3.org/2001/XMLSchema#string

F C Tenover

http://www.w3.org/2001/XMLSchema#string

J Johnston

http://www.w3.org/2001/XMLSchema#string

K Murfitt

http://www.w3.org/2001/XMLSchema#string

P Nelson

http://www.w3.org/2001/XMLSchema#string

R K Sall

http://www.w3.org/2001/XMLSchema#string

R V Spera

http://www.w3.org/2001/XMLSchema#string

P2860

Antibiotic-resistant Staphylococcus epidermidis in patients undergoing cardiac surgery.

An overview of nosocomial infections, including the role of the microbiology laboratory.

Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.

Characterization of glycopeptide-resistant enterococci from U.S. hospitals.

In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide

Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin.

Clinical and microbiologic aspects of serious infections caused by Staphylococcus epidermidis.

Emergence of vancomycin resistance in coagulase-negative staphylococci.

Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus.

In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin.

P304

167-170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/501605

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

1999-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10100541

http://www.w3.org/2001/XMLSchema#string